CROI 2025 will cover viral infections, treatments, and potential cures, focusing on HIV, COVID-19, STIs, and hepatitis C. The conference will feature plenary sessions on HIV research, global ...
Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and why this meeting is so important in this space. The 2025 Conference on ...
The MarketWatch News Department was not involved in the creation of this content. Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
Immunocore reports positive initial data for HIV treatment candidate IMC-M113V, showing safety and signs of viral control post-treatment. The observation of delayed viral rebound and/or viremia ...
Findings in HIV highlight AMV technology's versatility, robust immune response, and excellent safety profile, underpinning company’s expansion into oncology applications AMVs are a new class of ...
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented findings from the REPRIEVE trial about the use of ...
The major HIV conference in San Francisco this week coincides with growing fears that budget cuts being pushed by Republicans will gut essential health care services in the United States and worldwide ...
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results